Introduction to the APASL Clinical Guidelines on the Management of Metabolic-Associated Fatty Liver Disease

Y W Shi,Q,J G Fan

DOI: https://doi.org/10.3760/cma.j.cn51113-20201102-00592

2020-01-01

Abstract:Recently, metabolic-associated fatty liver disease has become the world’s highest prevalence of chronic liver disease. Moreover, it is closely related to metabolic syndrome and related diseases, bringing a huge disease burden. Previously, the global expert consensus on renaming for non-alcoholic fatty liver disease and the diagnostic criteria for metabolic-associated fatty liver disease has increased the certainty of further clinical research and practice. Presently, the research on metabolic-associated fatty liver disease is progressing rapidly, and the opinions and data based on clinical evidence are constantly updated. Hepatology international has published the "Asian Pacific Association for the Study of liver diseases’ clinical guidelines on the management of metabolic-associated fatty liver disease" , which aims to promote clinical practice and improve the efficiency of clinical research. Here, we have translated the published recommendations into Chinese language, hoping to help most health professionals make clinical decisions.